Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/MYH11 developing after exposure to irinotecan-containing chemoradiotherapy

Internal Medicine
Hiroki AkiyamaOsamu Miura

Abstract

A 40-year-old woman developed therapy-related acute myeloid leukemia (t-AML) with inv(16)(p13.1q22) and a rare type D form of core-binding factor β-subunit gene-myosin heavy chain 11 gene (CBFB-MYH11) fusion transcript approximately 2.5 years after receiving chemoradiotherapy for uterine cervical cancer. t-AML with inv(16)(p13.1q22) and rare non-type A CBFB-MYH11 typically develops after exposure to a topoisomerase II inhibitor, with a short period of latency of one to five years. As the patient had no history of exposure to topoisomerase II inhibitors, among her previously used chemotherapeutics, the topoisomerase I inhibitor, irinotecan, was speculated to be the most plausible cause of t-AML in this case. The present case suggests that irinotecan may cause t-AML resembling that associated with topoisomerase II inhibitors.

References

Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B QuesnelJ L Harousseau
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M DissingJ Pedersen-Bjergaard
Sep 28, 1998·Biochimica Et Biophysica Acta·C A Felix
Apr 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Frank GriesingerDetlef Haase
Nov 19, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y MerroucheJ-Y Cahn
Mar 10, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jörg T Hartmann, Hans-Peter Lipp
Sep 5, 2007·Haematologica·Giuseppe LeoneMaria Teresa Voso
Aug 12, 2009·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·Kazuyuki NumakuraNaoto Takahashi
Nov 3, 2010·British Journal of Pharmacology·H SillA Wölfler

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.